Document Detail

Target-based drug discovery, genetic diseases, and biologics.
MedLine Citation:
PMID:  22306775     Owner:  NLM     Status:  Publisher    
The last fifteen years have witnessed a major strategic shift in drug discovery away from an empiric approach based on incremental improvements of proven therapies, to a more theoretical, target-based approach. This arose as a consequence of three technical advances: (1) generation and interpretation of genome sequences, which facilitated identification and characterization of potential drug targets; (2) efficient production of candidate ligands for these putative targets through combinatorial chemistry or generation of monoclonal antibodies; and (3) high-throughput screening for rapid evaluation of interactions of these putative ligands with the selected targets. The basic idea underlying all three of these technologies is in keeping with Marshall Nirenberg's dictum that science progresses best when there are simple assays capable of generating large data sets rapidly. Furthermore, practical implementation of target-based drug discovery was enabled directly by technologies that either were originated or nurtured by Marshall, his post-docs and fellows. Chief among these was the genetic code. Also important was adoption of clonal cell lines for pharmacological investigations, as well as the use of hybridomas to generate molecular probes that allowed physical purchase on signaling elements that had previously been only hypothetical constructs. Always the pure scientist, Marshall's contributions nevertheless enabled fruitful applications in the pharmaceutical industry, several of them by his trainees. Both the successes and the shortcomings of target-based drug discovery are worthy of consideration, as are its implications for the choices of therapeutic goals and modalities by the pharmaceutical industry.
Orest Hurko
Related Documents :
22655585 - Drug-related problems identified by clinical pharmacist's students and pharmacist's int...
22478935 - Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal...
22420655 - Size estimation of chemical space: how big is it?
22537885 - Pharmacotherapy in medicare beneficiaries with atrial fibrillation.
19680525 - Will the evolution of overactive bladder delivery systems increase patient compliance?
21189135 - Targeting intestinal transporters for optimizing oral drug absorption.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-27
Journal Detail:
Title:  Neurochemistry international     Volume:  -     ISSN:  1872-9754     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-2-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006959     Medline TA:  Neurochem Int     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Ltd.
Biologics Consulting Group, Inc., 19 Sugar Knoll Drive, Devon, PA 19333-1558, USA; Biologics Consulting Group, Inc. (Central Office), 400 North Washington Street, Suite 100, Alexandria, VA 22314-2353, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Involvement of glucocorticoid-mediated Zn(2+) signaling in attenuation of hippocampal CA1 LTP by acu...
Next Document:  The glutamate transporter, GLAST, participates in a macromolecular complex that supports glutamate m...